Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The European Medicines Agency has announced the marketing authorization of Mycamine, Astellas Pharma Europe's treatment for invasive candidiasis, oesophageal candidiasis and prophylaxis of Candida infection in patients undergoing allogeneic haematopoietic stem cell transplantation.
Subscribe to our email newsletter
Mycamine will initially be available in the UK and across the European market shortly after this.
David Denning of the University of Manchester said: “The approval of micafungin is very good news for patients with life-threatening fungal infections in Europe. The company has conducted a number of large, high quality clinical studies in Candida infections with impressive results. Particularly welcome are the indications for fungal infections in children and babies, often a neglected group in the early drug approval process.”